$77.78
▼ -0.1% Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
HALO: Raising target price to $86.00
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Overview
52-week range
$51
$82
86% of range
Avg surprise (last 3)
+15.0%
Avg reaction (last 2)
+0.8%
50% positive
Latest IV / EM
42%
EM ±9.6% · $80 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $1.48 | $1.46 | +1.4% | +43.7% | +3.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.43 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $1.47 | $1.15 | +27.8% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $1.03 | $0.89 | +15.7% | — | -2.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.05 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.72 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.60 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.61 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.56 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | $1.73 | $1.47 | +17.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $79M | — | $55M | $46M | $48M | — | $49M | $40M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $185M | — | $218M | $202M | $142M | — | $163M | $117M |
| Net income | $150M | — | $175M | $165M | $118M | — | $137M | $93M |
| EPS (diluted) | $1.22 | — | $1.43 | $1.33 | $0.93 | — | $1.05 | $0.72 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $310M | $134M | $420M | $62M | $176M | $116M | $154M | $188M |
| Inventory | $155M | $176M | $186M | $182M | $165M | $142M | $131M | $159M |
| Total current assets | $1.00B | $825M | $1.33B | $1.12B | $1.26B | $1.09B | $1.13B | $988M |
| Total assets | $2.67B | $2.53B | $2.22B | $2.05B | $2.20B | $2.06B | $2.12B | $1.97B |
| Long-term debt | $1.94B | $2.14B | $800M | $1.51B | $1.51B | $1.51B | $1.50B | $1.50B |
| Total liabilities | $2.45B | $2.48B | $1.72B | $1.72B | $1.71B | $1.70B | $1.67B | $1.68B |
| Total equity | $220M | $49M | $504M | $333M | $482M | $364M | $453M | $289M |